Event Objectives:Apply the learned epidemiology and clinical presentation of Wilms Tumor to appropriate surveillance and/or diagnostic evaluation for children at known risk due to underlying genetic syndromes or with presentation of signs and symptoms consistent this diagnosis.Contextualize the current standard of care therapies for patients with Wilms Tumor with the history of discovery and first treatments and recognize the evolution of risk stratification as the backbone of clinical trial development in Wilms Tumor.Appraise the presented supporting data on prognostic features of outcomes for patients with Wilms Tumor and evaluate the incorporation of this information into the upcoming Children’s Oncology Group therapeutic protocol for the Risk Stratified Treatment of patients with Stage I- IV Favorable Histology Wilms Tumor.Discuss the presented interrelationship between organogenesis and tumorigenesis and spur innovative thought into the underlying biology of the spectrum of Wilms Tumor and nephroblastomatosis.Claim CME Credit Here!

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related